JUL 17, 2018 1:35 PM PDT

First Drug for Smallpox Treatment

WRITTEN BY: Nouran Amin

TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox, was just approved by the U.S. Food and Drug Administration to SIGA Technologies Inc. The development of TPOXX was in conjunction with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).

Even though eradicated in 1980, the World Health Organization (WHO) announced that smallpox as a contagious and sometimes fatal infectious disease that can be used as a bioweapon.

“To address the risk of bioterrorism, Congress has taken steps to enable the development and approval of countermeasures to thwart pathogens that could be employed as weapons. Today’s approval provides an important milestone in these efforts. This new treatment affords us an additional option should smallpox ever be used as a bioweapon,” said FDA Commissioner Scott Gottlieb, M.D. "This is the first product to be awarded a Material Threat Medical Countermeasure priority review voucher. Today’s action reflects the FDA’s commitment to ensuring that the U.S. is prepared for any public health emergency with timely, safe and effective medical products.”

Before its 1980 eradication, variola virus, the virus that leads to smallpox, it was mainly spread by direct contact between people. The symptoms typically began 10 to 14 days after infection and include fever, exhaustion, headache, and backache followed by a rash initially with small, pink bumps progressed to pus-filled sores before finally crusting over and scarring. Smallpox complications include encephalitis (inflammation of the brain), corneal ulcerations (an open sore on the clear, front surface of the eye) and blindness.

The efficacy of TPOXX against smallpox was concluded by studies on animals infected with viruses that are closely related to the virus that results in smallpox and was based on measuring survival at the end of the studies. The studies showed that the animals treated with TPOXX have survived compared to the animals treated with a placebo.

Using the FDA’s Animal Rule, which ensures efficacy are adequate from well-controlled animal research findings, TPOXX was approved.

TPOXX safety was evaluated using clinical trials on 359 healthy human volunteers without a smallpox infection and the most frequently reported side effects included a headache, nausea, and abdominal pain. Additionally, TPOXX received the Orphan Drug designation, which allows incentives to assist and inspire the development of drugs for rare diseases and a Material Threat Medical Countermeasure Priority Review Voucher, which provides additional incentives for specific medical products intended to treat or prevent harm from specific chemical, biological, radiological and nuclear threats.

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 10, 2019
Drug Discovery & Development
NOV 10, 2019
Promising Results for New Vaccine Against Dengue Fever
Dengue fever is an illness transmitted by mosquito bites. Affecting around 390 million people per year, if left untreated, its mortality rate is 20%. Altho...
NOV 25, 2019
Drug Discovery & Development
NOV 25, 2019
Darobactin: Promising New Drug to Combat Antibiotic Resistance
Every year, around 700,000 people are estimated to die from drug-resistant infections thanks to our overuse of antibiotics both in agriculture and medicine...
NOV 27, 2019
Drug Discovery & Development
NOV 27, 2019
New Painkiller More Effective than Opioids Discovered in Mud
Researchers have discovered a new painkiller dubbed to be as effective as opioids, only minus their disadvantages, from a 16-year old mud sample found near...
NOV 28, 2019
Drug Discovery & Development
NOV 28, 2019
Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer
By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have foun...
JAN 03, 2020
Drug Discovery & Development
JAN 03, 2020
New Drug Combo Reverses Breast Cancer
Researchers from Georgetown University have found that combining a drug used for epilepsy, bipolar disorder, and migraines with a drug used to ease blood p...
JAN 06, 2020
Drug Discovery & Development
JAN 06, 2020
Designing Drugs To Fight off C. Diff Infections
A study published by PNAS explains breakthrough research around designing drugs that target C. diff bacterial infections that result in 15,000 deaths in th...
Loading Comments...